Olink Holding AB Debuts Olink Target 48 Immune Surveillance Panel

Olink Holding AB (publ) (OLK), a pioneering force in the realm of life science research, has revealed the launch of its newest innovation, the Olink Target 48 Immune Surveillance panel. This cutting-edge multiplexed protein assay panel is a testament to the company's commitment to facilitating unparalleled precision in immune system analysis. The launch, which took place in Uppsala, Sweden, represents a strategic advancement in biotechnological tools designed for academic, biopharmaceutical, and research institutions.

Revolutionizing Immune Biomarker Profiling

With the introduction of the Olink Target 48 Immune Surveillance panel, researchers now have access to a powerful tool that enables thorough and accurate monitoring of immune system biomarkers. The well-validated panel ensures researchers can perform detailed assessments with absolute confidence. This technology holds great potential for contributing to the understanding of immune responses in various health conditions, thereby paving the path for the development of tailored therapeutics.

Empowering Researchers with Advanced Tools

The Olink Target 48 Immune Surveillance is the latest offering that reflects Olink Holding AB’s dedication to innovation in the life sciences sector. With its headquarters firmly established in Uppsala, Sweden, OLK continues to empower researchers around the world with sophisticated products and services that push the front schema of scientific discovery.

Olink, Immune, Biomarkers